Ye, X;
Shami, JJP;
Yan, VKC;
Kang, W;
Blais, JE;
Zhao, J;
Lau, WCY;
... Chan, EW; + view all
(2021)
Global antiplatelet sales trend: A focus on P2Y12 inhibitors from 2008 to 2018.
American Heart Journal Plus: Cardiology Research and Practice
, 4
, Article 100020. 10.1016/j.ahjo.2021.100020.
Preview |
Text
1-s2.0-S2666602221000185-main.pdf - Published Version Download (706kB) | Preview |
Abstract
BACKGROUND: P2Y12 inhibitors are an important component of dual antiplatelet therapy. Yet, their accessibility and affordability across countries stratified by income levels have not been studied. METHODS: Sales data were retrieved from the IQVIA Multinational Integrated Data Analysis System for the description of P2Y12 inhibitors global sales. Countries were stratified into 38 high-income countries and 27 middle-income countries. RESULTS: Global sales of P2Y12 inhibitors increased from 0.80 SU per year per person in 2008 to 1.79 in 2018. Growth in sales of P2Y12 inhibitors was greater in middle-income countries compared to high-income countries. Clopidogrel had the highest sales volume in both high-income and middle-income countries from 2008 to 2018, while ticagrelor sales volume increased mainly in high-income countries. CONCLUSIONS: Despite current guideline recommendations favoring ticagrelor and prasugrel for the prevention of atherothrombotic complications in patients with an acute coronary syndrome, clopidogrel retained the highest sales volume among the P2Y12 inhibitors from 2008 to 2018.
Archive Staff Only
 |
View Item |
